Maze Therapeutics, Inc. · NASDAQ:MAZE
Bernstein Harold sold 15,000 Maze Therapeutics, Inc. shares (Form 4)
Traded Apr 1, 2026 · Filed Apr 2, 2026
On Apr 1, 2026, Bernstein Harold (President, R&D & CMO) sold 15,000 Maze Therapeutics, Inc. shares at an average US$29.46 for US$442K under a trading plan, leaving 0 shares. Filed Apr 2, 2026 (Form 4).
- Sold
- 15,000 shares
- Price
- US$29.46 average (US$29.24 to US$31.07)
- Value
- US$442K
- Holding after
- 0 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- President, R&D & CMO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Common Stock | Option exercise | 15,000 | US$10.42 | 15,000 | Direct |
| Apr 1, 2026 | Common Stock | Sale | 11,352 | US$29.24 | 3,648 | Direct |
| Apr 1, 2026 | Common Stock | Sale | 3,348 | US$30.06 | 300 | Direct |
| Apr 1, 2026 | Common Stock | Sale | 300 | US$31.07 | 0 | Direct |
Source
Related
- Maze Therapeutics, Inc.
- Bernstein Harold
- Maze Therapeutics, Inc. shareholders
- Form 4 · Bernstein Harold · Oct 2, 2026
- Form 4 · Bernstein Harold · Sep 8, 2026
- Form 4 · Bernstein Harold · Sep 4, 2026
- Form 4 · Bernstein Harold · Sep 3, 2026
- Form 4 · Bernstein Harold · Aug 14, 2026
- Form 4 · Coloma Jason V · Oct 2, 2026
- Form 4 · Dandekar Atul · Oct 1, 2026
- Form 4 · Coloma Jason V · Sep 4, 2026
- Form 4 · Dandekar Atul · Sep 4, 2026
- Form 4 · Courtney Phillips · Sep 4, 2026